Is venetoclax a medically insured drug?

Venetoclax is a targeted therapy drug mainly used to treat certain types of hematological malignancies, especially chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML). It induces cancer cell apoptosis by inhibiting the activity of BCL-2 (BCL-2) protein, thereby reducing the number of cancer cells. Venetoclax is a small molecule oral drug that is often combined with other drugs such as obinutuzumab (Obinutuzumab) or low-dose chemotherapy drugs to improve efficacy.

Venetoclax is currently on the market in China and has been included in medical insurance. This means that eligible patients can be reimbursed for part of their drug costs through medical insurance, which greatly reduces the patient's financial burden. Specific medical insurance reimbursement ratios and policies vary by region. It is recommended that patients directly consult the local hospital pharmacy for detailed reimbursement information.

In China, the price of venetoclax is 100mg*28 tablets, which is about 2,000 yuan. Although the price has been reduced after being included in medical insurance, the cost of drugs is still relatively high for patients with long-term treatment.

Abroad, especially in countries that produce generic drugs such as Laos and Bangladesh, the price of generic venetoclax is relatively cheap. 100mg*120The price of generic drugs is about more than 2,000 yuan, which is more affordable than domestic prices. In addition, there are smaller generic versions available that cost only a few hundred yuan per bottle. Although the prices are low, the ingredients of these generic drugs are basically the same as those of the original drugs, and their therapeutic effects have been recognized by some patients.

In general, patients can choose domestic medical insurance-reimbursed drugs or foreign generic drugs according to their own conditions, but they should use the drugs rationally under the guidance of a doctor to ensure the effectiveness and safety of the treatment.